Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
- Equal contributors
1 Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada
2 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
3 Hereditary Cancer Program, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
4 Genetic Pathology Evaluation Centre of the Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada
5 Molecular Genetics, The Royal Melbourne Hospital, Parkville, Australia
6 Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, San Francisco, California, USA
7 Affymetrix Inc. 7300 Shoreline Blvd South, San Francisco, California, USA
8 Department of Gynecologic Oncology, University of British Columbia, Vancouver, British Columbia, Canada
Citation and License
BMC Cancer 2008, 8:17 doi:10.1186/1471-2407-8-17Published: 22 January 2008
Subclassification of ovarian carcinomas can be used to guide treatment and determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers. The mechanism of BRCA1/2 loss is a potential method of subclassifying high grade serous carcinomas.
A consecutive series of 49 ovarian cancers was assessed for mutations status of BRCA1 and BRCA2, LOH at the BRCA1 and BRCA2 loci, methylation of the BRCA1 promoter, BRCA1, BRCA2, PTEN, and PIK3CA transcript levels, PIK3CA gene copy number, and BRCA1, p21, p53, and WT-1 immunohistochemistry.
Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1. All of these tumours were high-grade serous or undifferentiated type. None of the endometrioid (n = 5), clear cell (n = 4), or low grade serous (n = 2) carcinomas showed loss of BRCA1, whereas 47% of the 38 high-grade serous or undifferentiated carcinomas had loss of BRCA1. It was possible to distinguish high grade serous carcinomas with BRCA1 mutations from those with epigenetic BRCA1 loss: tumours with BRCA1 mutations typically had decreased PTEN mRNA levels while those with epigenetic loss of BRCA1 had copy number gain of PIK3CA. Overexpression of p53 with loss of p21 expression occurred significantly more frequently in high grade serous carcinomas with epigenetic loss of BRCA1, compared to high grade serous tumors without loss of BRCA1.
High grade serous carcinomas can be subclassified into three groups: BRCA1 loss (genetic), BRCA1 loss (epigenetic), and no BRCA1 loss. Tumors in these groups show distinct molecular alterations involving the PI3K/AKT and p53 pathways.